曲妥珠单抗联合吉西他滨或卡培他滨一线治疗HER—2阳性晚期乳腺癌的临床研究(3)

http://www.100md.com 2017年5月5日 《中国当代医药》2017年第13期

     [6]Martin M，Makhson A，Gligorov J，et al.Phase Ⅱ study of bevaci-zumab in combination with trastuzumab and capec？鄄itabine as first line treatment for HER-2-positive locally recurrent or metastatic breast cancer[J].Oncologist ......